CytaCoat
Sergey Surkov is a microbiologist with extensive experience in molecular genetics and bacterial research. Currently employed at CytaCoat since April 2020, Sergey focuses on microbiological applications. Prior to this role, Sergey worked as a postdoctoral researcher at Uppsala University from April 2017 to April 2020, investigating de novo gene evolution in bacteria utilizing various advanced methodologies. Sergey held a postdoctoral position at the National Cancer Institute from April 2011 to April 2016, where research centered on the N-end rule pathway of protein degradation. Sergey began academic training at Stockholm University, completing a PhD in Molecular Genetics in 2010, focusing on translation initiation and trans-translation. Throughout the career, Sergey has gained expertise in techniques such as strain construction, mutagenesis, RNA isolation, mass spectrometry, and other biochemical assays.
This person is not in the org chart
This person is not in any offices
CytaCoat
1 followers
CytaCoat is developing a new technology of antibacterial coating for medical devices. CytaCoat AB is a private Swedish company located in the Karolinska Institutet Science Park AB in Solna (Stockholm area). The company was founded by a group of researchers from the Karolinska Institute, one of the foremost medical universities in the world, and theRoyal Institute of Technology (KTH). It was a special purpose vehicle started with a goal to develop a new technology of antibacterial coating for medical devices. It was based on a discovery that their proprietary polymer surface exhibits a clear effect on several of the most problematic pathogenic bacteria that pose problems in healthcare today. Since then, the company has been focused on transforming this innovation into a fully viable commercial product and make it available through licenses.CytaCoat has a fully equipped laboratory in the Karolinska Institutet Science Park, where both microbiology evaluation, optimisation of the CytaCoat technology and a pilot plant production can be performed. The company has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. CytaCoat has also been cooperating with experienced consultants in regulatory, clinical research organisations, patent experts and providers of specialist analyses.